tbuckley/cabot-search huggingface dataset:
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care
Authors: Wilfried Mullens, Angelo Auricchio, Pieter Martens, Klaus Witte, Martin R. Cowie, Victoria Delgado, Kenneth Dickstein, Cecilia Linde, Kevin Vernooy, Francisco Leyva, Johann Bauersachs, Carsten W. Israel, Lars H. Lund, Erwan Donal, Giuseppe Boriani, Tiny Jaarsma, Antonio Berruezo, Vassil Traykov, Zaheer Yousef, Zbigniew Kalarus, Jens Cosedis Nielsen, Jan Steffel, Panos Vardas, Andrew Coats, Petar Seferovic, Thor Edvardsen, Hein Heidbuchel, Frank Ruschitzka, Christophe Leclercq
Journal: European Journal of Heart Failure (2020)

Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart failure with reduced ejection fraction and leads to improved quality of life, reductions in heart failure hospitalization rates and all-cause mortality. Nevertheless, up to two-thirds of eligible patients are not referred for CRT. Furthermore, post-implantation follow-up is often fragmented and suboptimal, hampering the potential maximal treatment effect. This joint position statement from three European Society of Cardiology Associations, Heart Failure Association (HFA), European Heart Rhythm Association (EHRA) and European Association of Cardiovascular Imaging (EACVI), focuses on optimized implementation of CRT. We offer theoretical and practical strategies to achieve more comprehensive CRT referral and post-procedural care by focusing on four actionable domains: (i) overcoming CRT under-utilization, (ii) better understanding of pre-implant characteristics, (iii) abandoning the term 'non-response' and replacing this by the concept of disease modification, and (iv) implementing a dedicated post-implant CRT care pathway.
Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia
Authors: Moritz Binder, Ryan M. Carr, Terra Lasho, Christy Finke, Abhishek A. Mangaonkar, Christopher Pin, Kurt Berger, Tamas Ordog, Bonnie Alver, Keith Robertson, David Marks, Martin Fernandez-Zapico, Alexandre Gaspar Maia, Mrinal M. Patnaik
Journal: Blood (2020)
Vector Shedding and Blood Biodistribution in Patients with Severe Hemophilia a Following Administration of Valoctocogene Roxaparvovec
Authors: Annie Clark, Kevin Hammon, Krystal Sandza, Richard Torres, Elli Koziol, Jennifer Holcomb, Benjamin Kim, Kala Jayaram, Chris Russell, Christian Vettermann, Joshua Henshaw
Journal: Blood (2020)
Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis
Authors: Min Ma, Soumitra Ghosh, Daniele Tavernari, Atul Katarkar, Andrea Clocchiatti, Luigi Mazzeo, Anastasia Samarkina, Justine Epiney, Yi-Ru Yu, Ping-Chih Ho, Mitchell P. Levesque, Berna C. Özdemir, Giovanni Ciriello, Reinhard Dummer, G. Paolo Dotto
Journal: The Journal of Experimental Medicine (2020)

Melanoma susceptibility differs significantly in male versus female populations. Low levels of androgen receptor (AR) in melanocytes of the two sexes are accompanied by heterogeneous expression at various stages of the disease. Irrespective of expression levels, genetic and pharmacological suppression of AR activity in melanoma cells blunts proliferation and induces senescence, while increased AR expression or activation exert opposite effects. AR down-modulation elicits a shared gene expression signature associated with better patient survival, related to interferon and cytokine signaling and DNA damage/repair. AR loss leads to dsDNA breakage, cytoplasmic leakage, and STING activation, with AR anchoring the DNA repair proteins Ku70/Ku80 to RNA Pol II and preventing RNA Pol II–associated DNA damage. AR down-modulation or pharmacological inhibition suppresses melanomagenesis, with increased intratumoral infiltration of macrophages and, in an immune-competent mouse model, cytotoxic T cells. AR provides an attractive target for improved management of melanoma independent of patient sex.
Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma
Authors: Burhan Ferhanoglu, Tae Min Kim, Amado Karduss, David Brittain, Gayane Tumyan, Mubarak Al Mansour, Marta Zerga, Yuqin Song, Silvia Rivas-Vera, Yok Lam Kwong, Soon Thye Lim, Su-Peng Yeh, Arif Abdillah, Zhongwen Huang, Mehul Dalal, Hui Wan, Mark Hertzberg
Journal: Blood (2020)
AB0058 Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis
Authors: S Nakazaki, T Murayama, S Katoh
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> MTX has gained wide acceptance of the most useful disease-modifying anti-rheumatic drugs. But, MTX cause serious toxicities including hepatic abnormalities, pneumonitis, and myelosuppression. <h3>Objectives</h3> To assess the associated risk factors of methotrexate (MTX)-induced cytopenia in rheumatoid arthritis (RA). <h3>Methods</h3> We followed 420 patients started on MTX for RA. We evaluated the frequency and clinical significance of patients with cytopenia related to MTX therapy. <h3>Results</h3> The prevalence of patients remaining in the follow-up in the MTX treatment was 21% at 60 months. A total of 10 patients with cytopenia related to MTX therapy were identified among them. The prevalence of cytopenia, including leukopenia (n = 6), thrombocytopenia (n = 3) and pancytopenia (n = 1), estimated to be 2.4% in MTX treated RA patients. Patients with cytopenia received 2.5‑8 mg/w over a mean duration of 60.0 months (10‑119 months). Nine of 10 patients received NSAIDs with MTX therapy. The presence of renal abnormality (Cr &gt;1.2 mg/d) was in 3 cases, age over 70 years old in 4 patients, body weight under 50 kg in 8 patients, mean corpuscular volume (MCV) over 100 fl in 2 patients. High MCV value (over 94 fl) was in 7 patients, 6 of whom had some symptoms including fever (n = 3) and oral mucosa/lip abnormalities (n = 3). Low MCV value (under 84 fl) was in 3 patients, who had no symptoms but arthralgia and no renal abnormality. And they were younger and received MTX in shorter period than high MCV group. <h3>Conclusion</h3> In patients with high MCV (over 94 fl), most haematological toxicities seen during the course of MTX therapy can be predictable. But, some patients may develop unpredictable haematological reaction. <h3>References</h3> American College of Rheumatology ad hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723–31 Gutierrez-Urena S, Molina Cesar JF, Garcia O. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:272–6
Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls
Authors: Urvi A Shah, Sæmundur Rögnvaldsson, Andriy Derkach, Magnus Björkholm, Ingemar Turesson, Yael David, Malin Hultcrantz, Carlyn Tan, Hani Hassoun, Neha Korde, Alexander M. Lesokhin, Sham Mailankody, Sigurður Yngvi Kristinsson, Ola Landgren
Journal: Blood (2020)
Omitting Fluoroquinolones Antibiotic Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Increase Gram-Negative Bacteremia Rate or Transplant-Related Mortality
Authors: Israel Henig, Oryan Henig, Haggai Bar-Yoseph, Hanin Daoud, Dana Yehudai-Ofir, Ilana Oren, Tsila Zuckerman
Journal: Blood (2020)
Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study
Authors: Michael J. Mauro, Vivian G. Oehler, James E. Thompson, James K. McCloskey, Michael C. Heinrich, Shaker R. Dakhil, Irene DeGutis, David Tabano, Wasiulla Khan, Javid J. Moslehi
Journal: Blood (2020)
SP0174 Patients’ influence on health care, and social care
Authors: DD Magnusson
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> A short presentation of how a Rheumatism NGO can work on a local level together with the County Council, the Health Care Employment Service Agency and the Social Insurance Office. Together with the health professionals we have produced education material, which is possible to use for health professionals, patients, the Employment Service Agency, the Social Insurance Office and the County Council. This material is called "For whom (it may concern)". The book has 12 chapters which contains these subjects: Humanity, quality of life, for whom, whose goals, meeting people, to take responsibility – right to self-determination, to make demands, who has the authority, rehabilitation economy, following up and evaluation, conventions, laws and regulations. The material contains four parts in each chapter, the first part is sayings, the second part is a factual part, the third part is a case example, the fourth part is a number of questions which are solutions orientated. Everyone can use this material, alone or in groups. We are functioning, as patient experts on matters like, rehabilitation, education and how to approach the patient. My experience is from a region in the middle of Sweden called Jamtland. Jamtland has a big area on 49 500 km² with a population of 129 000 people, which means 2,6 persons per square kilometre.
Uncertain evolution of untreated coronary syndromes during covid-19 pandemic
Authors: José Ramón Seco Vasco, Raul Curado Castano, Ana Maria Mateos Gomez
Journal: BMJ (2020)

ATP, coreleased with norepinephrine, affects adrenergic transmission by acting on purinoceptors at sympathetic nerve endings. Ectonucleotidases terminate the actions of ATP. Previously, we had preliminary evidence for ectonucleotidase activity in cardiac sympathetic nerve terminals. Therefore, we investigated whether this ectonucleotidase might influence norepinephrine release in the heart. Sympathetic nerve endings isolated from guinea pig heart (cardiac synaptosomes) were rich in Ca<sup>2+</sup>-dependent ectonucleotidase activity, as measured by metabolism of exogenously added radiolabeled ATP or ADP. By its inhibitor profile, ectonucleotidase resembled ectonucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1). Exogenous ATP elicited concentration-dependent norepinephrine release from cardiac synaptosomes (EC<sub>50</sub> 0.96 μM). This release was antagonized by the P2X receptor antagonist pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS) (10 μM) and potentiated by the P2Y receptor antagonist 2′-deoxy-<i>N</i><sup>6</sup>-methyladenosine-3′,5′-diphosphate (MRS 2179) (30 nM). Norepinephrine release promoted by ATP was also potentiated by the nucleotidase inhibitor 6-<i>N</i>,<i>N</i>-diethyl-β-γ-dibromomethylene-d-adenosine-5′-triphosphate (ARL67156) (30 μM) and blocked by a recombinant, soluble form of human E-NTPDase1 (solCD39). In contrast, ARL67156 had no effect on norepinephrine release induced by the nonhydrolyzable analog, α, β-methyleneadenosine-5′-triphosphate (α,β-MeATP). Depolarization of cardiac synaptosomes with K<sup>+</sup> elicited release of endogenous norepinephrine. This was attenuated by PPADS and solCD39 and potentiated by MRS 2179 and ARL67156. Importantly, our results demonstrate that facilitation of ATP-induced norepinephrine release from cardiac sympathetic nerves is a composite of two autocrine components: positive, mediated by P2X receptors, and negative, mediated by P2Y receptors. Modulation of norepinephrine release by coreleased ATP is terminated by endogenous as well as exogenous ectonucleotidase. We propose that ectonucleotidase control of norepinephrine release should provide cardiac protection in hyperadrenergic states such as myocardial ischemia.
Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress
Authors: Adrian C. Newland, Howard A. Liebman, Vickie McDonald, Marc Michel, Yoshitaka Miyakawa, Wim Parys, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter
Journal: Blood (2020)
Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo
Authors: Ralf Buettner, Le Xuan Truong Nguyen, Corey James Morales, Lisa S Chen, Timothy Synold, Dinh Hoa Hoang, Bin Amber Zhang, Lucy Ghoda, Varsha Gandhi, Vinod A. Pullarkat, Guido Marcucci, Steven T. Rosen
Journal: Blood (2020)
Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial
Authors: Marc S. Raab, Nicola Giesen, Christof Scheid, Britta Besemer, Kaya Miah, Axel Benner, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Hartmut Goldschmidt, Katja Weisel, Manik Chatterjee
Journal: Blood (2020)
Associations between high temperatures in pregnancy and risk of preterm birth, low birth weight, and stillbirths: systematic review and meta-analysis
Authors: Matthew Francis Chersich, Minh Duc Pham, Ashtyn Areal, Marjan Mosalam Haghighi, Albert Manyuchi, Callum P Swift, Bianca Wernecke, Matthew Robinson, Robyn Hetem, Melanie Boeckmann, Shakoor Hajat
Journal: BMJ (2020)

Abstract Objective To assess whether exposure to high temperatures in pregnancy is associated with increased risk for preterm birth, low birth weight, and stillbirth. Design Systematic review and random effects meta-analysis. Data sources Medline and Web of Science searched up to September 2018, updated in August 2019. Eligibility criteria for selecting studies Clinical studies on associations between high environmental temperatures, and preterm birth, birth weight, and stillbirths. Results 14 880 records and 175 full text articles were screened. 70 studies were included, set in 27 countries, seven of which were countries with low or middle income. In 40 of 47 studies, preterm births were more common at higher than lower temperatures. Exposures were classified as heatwaves, 1°C increments, and temperature threshold cutoff points. In random effects meta-analysis, odds of a preterm birth rose 1.05-fold (95% confidence interval 1.03 to 1.07) per 1°C increase in temperature and 1.16-fold (1.10 to 1.23) during heatwaves. Higher temperature was associated with reduced birth weight in 18 of 28 studies, with considerable statistical heterogeneity. Eight studies on stillbirths all showed associations between temperature and stillbirth, with stillbirths increasing 1.05-fold (1.01 to 1.08) per 1°C rise in temperature. Associations between temperature and outcomes were largest among women in lower socioeconomic groups and at age extremes. The multiple temperature metrics and lag analyses limited comparison between studies and settings. Conclusions Although summary effect sizes are relatively small, heat exposures are common and the outcomes are important determinants of population health. Linkages between socioeconomic status and study outcomes suggest that risks might be largest in low and middle income countries. Temperature rises with global warming could have major implications for child health. Systematic review registration PROSPERO CRD 42019140136 and CRD 42018118113.
Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison
Authors: Siddharth Bhesania, Silpa Anand, Tanveer Dabria, Swathi Veliginti, Sahithi Nadella, Nikhil Kumar Kotla, Pritika Manaktala, Chanoa Medina, Janki Bhesania, Achint Patel, Angelica Singh, Parag Mehta, Eshan Patel
Journal: Blood (2020)
Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma
Authors: Samer A. Srour, Yago Nieto, Swaminathan P Iyer, Roberto N. Miranda, Farzaneh Maadani, Gabriela Rondon, Neeraj Saini, Paolo Strati, May Daher, Ranjit Nair, Bouthaina S. Dabaja, Uday R. Popat, Muzaffar H. Qazilbash, Elizabeth J. Shpall, Christopher Flowers, Richard E. Champlin, Chitra Hosing, Issa F. Khouri
Journal: Blood (2020)
Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
Authors: Pier Luigi Zinzani, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A Reeves, Wanda Knopinska-Posluszny, Chan Yoon Cheah, Tycel J. Phillips, Ewa Lech-Marańda, Bruce D. Cheson, Paolo F Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chavez, Gustavo A. Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P Sharman, Jennie Y. Law, John M. Pagel, Owen A. O'Connor, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Nathan H Fowler
Journal: Blood (2020)
Haploidentical Mbil-21 <i>Ex Vivo</i> Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia
Authors: Stefan O. Ciurea, Jolie Schafer, Piyanuch Kongtim, Julianne Chen, Doris Soebbing, Kai Cao, Samer A. Srour, Elizabeth J. Shpall, Marina Konopleva, Dean Anthony Lee, Richard E. Champlin
Journal: Blood (2020)
A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Peter Hillmen, Hope Qamoos, Anne Uyei, Wayne M. Rothbaum, Wojciech Jurczak, Catherine Thieblemont, John C. Byrd
Journal: Blood (2020)
Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy
Authors: Marianna De Muro, Sergio Amadori, Nicolina Rita Ardu, Elisabetta Cerchiara, Paolo De Fabritiis, Pasquale Niscola, Sabatino Dante, Valentina Schittone, Cristiano Tesei, Malgorzata Monika Trawinska, Elisabetta Abruzzese
Journal: Blood (2020)
FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma
Authors: Jode P Goodridge, Ryan Bjordahl, Sajid Mahmood, John Reiser, Svetlana Gaidarova, Robert Blum, Frank Cichocki, Hui-yi Chu, Greg Bonello, Tom Lee, Brian Groff, Miguel Meza, Yu-Waye Chu, Bruce Walcheck, Karl-Johan Malmberg, Jeffrey S. Miller, Armin Rehm, Uta Hopken, Bahram Valamehr
Journal: Blood (2020)
A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma
Authors: Lawrence Liu, Gao Feng, Mark A. Fiala, Justin King, Scott R. Goldsmith, Tanya M. Wildes, Keith E. Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder
Journal: Blood (2020)
Pancoronary Plaque Characteristics in STEMI Caused by Culprit Plaque Erosion Versus Rupture
Authors: Muhua Cao, Linlin Zhao, Xuefeng Ren, Tianyu Wu, Guang Yang, Zhuo Du, Huai Yu, Jiannan Dai, Lulu Li, Yini Wang, Guo Wei, Lijia Ma, Lei Xing, Yingfeng Tu, Shaohong Fang, Jinwei Tian, Haibo Jia, Gary S. Mintz, Bo Yu
Journal: JACC. Cardiovascular imaging (2020)
Abstract 14740: Achieving Guideline-Directed Therapy in U.S. Patients With Diabetes and Cardiovascular Disease: Alarming Gaps, Compelling Opportunities
Authors: Maddalena Ardissino, Adam J Nelson, Kevin Haynes, Zubin Eapen, Sonali Shambhu, Anthony Carnicelli, Emily C O’Brien, Renato D Lopes, Jennifer Green, Darren K McGuire, Neha Pagidipati, Christopher B Granger
Journal: Circulation (2019)

Background: Type 2 diabetes mellitus (T2DM) is among the largest and fastest growing causes of morbidity in the United States. Atherosclerotic cardiovascular disease (ASCVD) is widely known as a mo...
Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy
Authors: Naveen Pemmaraju, Boyd Mudenda, Cunlin Wang, Jiao JI, Ming Lu, Tommy Fu, Eric Liang, Sasha McClain, Piyush Sheladia, Srdan Verstovsek, Dajun Yang, Yifan Zhai
Journal: Blood (2020)
First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency
Authors: Rajni Agarwal, Kenneth I. Weinberg, Hye-Sook Kwon, Anne Le, Janel R Long-Boyle, Donald B. Kohn, Kathryn Bradford, Satiro De Oliveira, Alice Bertaina, Agnieszka Czechowicz, Matt Porteus, David C Shyr, Katja G Weinacht, Ami J Shah, Melissa Mavers, Elisabeth Merkel, Janice W Brown, Christopher C. Dvorak, Robertson Parkman, Maria Grazia Roncarolo, Judith A Shizuru
Journal: Blood (2020)
Control of Fetal Hemoglobin Levels By NFI Transcription Factors
Authors: Kunhua Qin, Peng Huang, Anran Huang, Ruopeng Feng, Thiyagaraj Mayuranathan, Cheryl A. Keller, Belinda Giardine, Ross C. Hardison, Mitchell J. Weiss, Junwei Shi, Gerd A. Blobel
Journal: Blood (2020)
Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients
Authors: Neha Korde, Elizabet Tavitian, Andriy Derkach, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Alexander M. Lesokhin, Nikoletta Lendvai, Eric L Smith, Malin Hultcrantz, Sydney X. Lu, Carlyn Tan, Urvi A Shah, Benjamin Diamond, Dhwani Patel, Gunjan L. Shah, Sergio A. Giralt, Sean Devlin, Thomas Atkinson, Joseph Lengfellner, Ola Landgren
Journal: Blood (2020)
Distinct Genomic Landscape of Chinese Pediatric Acute Myeloid Leukemia
Authors: Ting Liu, Jianan Rao, Wenting Hu, Yuhan Liu, Huiying Sun, Xiaoxiao Chen, Yanjing Tang, Jing Chen, Xiang Wang, Han Wang, Wubin Qian, Binchen Mao, Sheng Guo, Ronghua Wang, Yu Liu, Shuhong Shen
Journal: Blood (2020)
Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study
Authors: Giorgina Specchia, Patrizia Pregno, Massimo Breccia, Chiara Monagheddu, Fausto Castagnetti, Massimiliano Bonifacio, Mario Tiribelli, Fabio Stagno, Giovanni Caocci, Bruno Martino, Luigiana Luciano, Michele Pizzuti, Antonella Gozzini, Anna Rita Scortechini, Francesco Albano, Micaela Bergamaschi, Isabella Capodanno, Andrea Patriarca, Carmen Fava, Giovanna Rege Cambrin, Federica Sorà, Sara Galimberti, Monica Bocchia, Gianni Binotto, Giovanni Reddiconto, Attilio Guarini, Alessandro Maggi, Grazia Sanpaolo, Maria Stella De Candia, Valentina Giai, Elisabetta Abruzzese, Maria Cristina Miggiano, Franca Falzetti, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, Luciano Levato, Olga Mulas, Fabio Saccona, Gianantonio Rosti, Pellegrino Musto, Francesco Di Raimondo, Fabrizio Pane, Robin Foà, Michele Baccarani, Giovannino Ciccone, Giuseppe Saglio
Journal: Blood (2020)